# Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Influence of Habitual Food

**Authors:** Naiade S. Almeida, Raquel Rocha, Carla Daltro, Helma P. Cotrim

PMC · DOI: 10.3390/diagnostics15212711 · Diagnostics · 2025-10-27

## TL;DR

This study explores the link between dietary habits and sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease.

## Contribution

The study investigates the association between habitual food consumption and sarcopenia in MASLD patients, a relationship that remains underexplored.

## Key findings

- Only two MASLD patients were diagnosed with sarcopenia, while 27.6% had probable sarcopenia.
- Lower calcium intake was observed in MASLD patients with probable sarcopenia compared to those without sarcopenia.
- Most MASLD patients had lower calcium, energy, and protein intake.

## Abstract

Background: Sarcopenia is a clinical condition linked to various liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD includes a spectrum from steatosis to steatohepatitis, which may progress to fibrosis, cirrhosis, and hepatocellular carcinoma. The influence of dietary habits and nutrient intake on MASLD and its progression is well-established. However, the association between dietary consumption and sarcopenia in MASLD patients remains underexplored. This study evaluated whether there is an association between sarcopenia and habitual food consumption in MASLD patients. Methods: A cross-sectional study was conducted with outpatients diagnosed with MASLD. Sarcopenia was defined based on the 2019 EWGSOP2 criteria. Dietary intake was assessed using three 24 h recalls per patient, with intrapersonal variance corrected using the Multiple Source Method (MSM) software (Version 1.0.1). Steatosis was diagnosed via upper abdominal ultrasound, and the Fibrosis-4 Index (FIB-4) was used to assess hepatic fibrosis. Results: MASLD patients (n = 76) were evaluated. The mean age was 52.9 (SD, 12.0) years, and 75.0% were female. Two had sarcopenia, and 27.6% (n = 21) had probable sarcopenia (characterized by low muscle strength only). Among probable sarcopenia, F1-F2 were observed in 61.9%, and 23.8% had indeterminate FIB-4 grades. Calcium intake was lower among patients with probable sarcopenia than those no sarcopenia (p = 0.04). Conclusions: In these MASLD patients, only two patients were diagnosed with sarcopenia, and around a third had probable sarcopenia. The majority of MASLD patients with lower calcium, energy, and protein intake, but only lower calcium intake in those with probable sarcopenia.

## Linked entities

- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Diseases:** hepatic fibrosis (MESH:D008103), Sarcopenia (MESH:D055948), hepatocellular carcinoma (MESH:D006528), MASLD (MESH:D008107), Steatosis (MESH:D005234), Fibrosis (MESH:D005355)
- **Chemicals:** Calcium (MESH:D002118)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12611032/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12611032/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12611032/full.md

---
Source: https://tomesphere.com/paper/PMC12611032